Q4 2024 · 13F-HR
Paradigm Biocapital Advisors LPholdings as filed
Filed 2025-02-14 · accession 0001855655-25-000004
$2.87B
Reported value
28
Positions
2024-12-31
Period end
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 670703107 | NUVL | NUVALENT INC | $419.8M | 14.6% | 5,363,379 | Common | SOLE |
| 03940C100 | ACLXGBX | ARCELLX INC | $335.3M | 11.7% | 4,371,601 | Common | SOLE |
| 04016X101 | ARGX | ARGENX SE | $296.0M | 10.3% | 481,305 | Common | SOLE |
| 76155X100 | RVMD | REVOLUTION MEDICINES INC | $286.6M | 9.97% | 6,553,111 | Common | SOLE |
| 47103J105 | JANX | JANUX THERAPEUTICS INC | $188.2M | 6.55% | 3,515,986 | Common | SOLE |
| 87650L103 | TARS | TARSUS PHARMACEUTICALS INC | $140.2M | 4.88% | 2,531,896 | Common | SOLE |
| 28036F105 | EWTX | EDGEWISE THERAPEUTICS INC | $120.0M | 4.17% | 4,493,929 | Common | SOLE |
| 92243G108 | PCVX | VAXCYTE INC | $116.5M | 4.05% | 1,422,787 | Common | SOLE |
| 07725L102 | ONC | BEIGENE LTD | $113.8M | 3.96% | 616,024 | Common | SOLE |
| 22663K107 | CRNX | CRINETICS PHARMACEUTICALS IN | $97.7M | 3.40% | 1,910,761 | Common | SOLE |
| 61559X104 | MLTX | MOONLAKE IMMUNOTHERAPEUTICS | $96.0M | 3.34% | 1,772,211 | Common | SOLE |
| 254604101 | IRON | DISC MEDICINE INC | $95.0M | 3.30% | 1,497,720 | Common | SOLE |
| N5749R100 | 2GH | MERUS N V | $71.1M | 2.47% | 1,689,922 | Common | SOLE |
| 92337R101 | VERA | VERA THERAPEUTICS INC | $60.8M | 2.11% | 1,437,339 | Common | SOLE |
| 03770N101 | APGE | APOGEE THERAPEUTICS INC | $58.2M | 2.02% | 1,283,766 | Common | SOLE |
| 68062P106 | OLMA | OLEMA PHARMACEUTICALS INC | $42.6M | 1.48% | 7,304,970 | Common | SOLE |
| 729139105 | PLRX | PLIANT THERAPEUTICS INC | $42.1M | 1.46% | 3,197,050 | Common | SOLE |
| N44445109 | IMTX | IMMATICS N.V | $38.5M | 1.34% | 5,414,409 | Common | SOLE |
| 19240Q201 | COGT | COGENT BIOSCIENCES INC | $38.4M | 1.33% | 4,917,412 | Common | SOLE |
| 00773J202 | SYRE | SPYRE THERAPEUTICS INC | $35.6M | 1.24% | 1,527,205 | Common | SOLE |
| 92790C104 | VRDN | VIRIDIAN THERAPEUTICS INC | $34.9M | 1.21% | 1,820,079 | Common | SOLE |
| 984241109 | YMABUSD | Y-MABS THERAPEUTICS INC | $33.2M | 1.15% | 4,236,346 | Common | SOLE |
| 29479A108 | ERAS | ERASCA INC | $27.0M | 0.94% | 10,752,354 | Common | SOLE |
| 878972108 | TECX | TECTONIC THERAPEUTIC INC | $22.4M | 0.78% | 485,105 | Common | SOLE |
| 52635N103 | LENZ | LENZ THERAPEUTICS INC | $22.2M | 0.77% | 770,455 | Common | SOLE |
| 80706P103 | SRRK | SCHOLAR ROCK HLDG CORP | $17.3M | 0.60% | 400,000 | Common | SOLE |
| 687604108 | ORKA | ORUKA THERAPEUTICS INC | $15.9M | 0.55% | 819,660 | Common | SOLE |
| 00847X104 | AGIO | AGIOS PHARMACEUTICALS INC | $9.1M | 0.32% | 276,439 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.